ABT logo Abbott Laboratories +
Abbott Laboratories
+

Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

Zacks Investment Research

10:15 AM | Monday | Jul 13, 2026

news photo
Loading...

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Read full article redirect
10:15 AM | Monday | Jul 13, 2026

Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

Zacks Investment Research

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Read full article arrow
News Thumbnail
2:18 PM | Friday | Jul 10, 2026

Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment

24/7 Wall Street

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.

Read full article arrow
News Thumbnail
10:31 AM | Thursday | Jul 9, 2026

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

Zacks Investment Research

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read full article arrow
News Thumbnail
5:03 PM | Wednesday | Jul 8, 2026

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.

Read full article arrow
News Thumbnail
5:30 PM | Tuesday | Jul 7, 2026

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

The Motley Fool

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

Read full article arrow
News Thumbnail
2:00 PM | Tuesday | Jul 7, 2026

5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years

Fool - Investing News

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

Read full article arrow
News Thumbnail
10:01 AM | Monday | Jul 6, 2026

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
8:30 AM | Monday | Jul 6, 2026

3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

Fool - Investing News

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

Read full article arrow
News Thumbnail
4:00 PM | Friday | Jul 3, 2026

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

Seeking Alpha

Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.
38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.

Read full article arrow
News Thumbnail
8:18 AM | Thursday | Jul 2, 2026

5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential

24/7 Wall Street

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Read full article arrow
News Thumbnail